Abstract | BACKGROUND: OBJECTIVE: We conducted this study to assess TMB as a biomarker for PD-1/ PD-L1 inhibitor treatment in advanced NSCLC patients in a real-world setting. PATIENTS AND METHODS: Chinese NSCLC patients who received a PD-1/ PD-L1 inhibitor at the People's Liberation Army General Hospital and who had pathological tissues available for TMB were retrospectively analyzed. Demographic and clinical information were evaluated. Targeted next-generation sequencing (NGS) of the tumor tissue was performed. The relationship between TMB and clinical benefit was assessed. RESULTS: Thirty-four patients treated with PD-1/ PD-L1 inhibitors between March 2015 and January 2019 were analyzed. The TMB was greater in patients with complete response (CR)/partial response (PR) versus stable disease (SD) versus progressive disease (PD) (median 11 vs. 9.7 vs. 4.2 mutations/megabase [Mb]; p = 0.049). The median progression-free survival was 10.6 months in the TMB-high group versus 3.9 months in the TMB-low group (cut-off value = 10 mutations/Mb) (hazard ratio [HR] 0.26 [95% confidence interval 0.12-0.57], p = 0.0007). The median overall survival was 21.0 months and 11.6 months (HR 0.37 [0.17-0.81], p = 0.0126) in the TMB-high group and the TMB-low group, respectively. The disease control rate was higher in the TMB-high group than in the TMB-low group (100% vs. 70%, p = 0.024). CONCLUSIONS: High TMB was associated with a better outcome in advanced NSCLC patients who received PD-1/ PD-L1 inhibitors in China. Further studies are needed to confirm our findings.
|
Authors | Di Huang, Fan Zhang, Haitao Tao, Sujie Zhang, Junxun Ma, Jinliang Wang, Zhefeng Liu, Pengfei Cui, Shixue Chen, Ziwei Huang, Zhaozhen Wu, Lei Zhao, Yi Hu |
Journal | Targeted oncology
(Target Oncol)
Vol. 15
Issue 1
Pg. 93-100
(02 2020)
ISSN: 1776-260X [Electronic] France |
PMID | 32052340
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- Programmed Cell Death 1 Receptor
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(metabolism)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Female
- Humans
- Immunotherapy
(methods)
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Programmed Cell Death 1 Receptor
(antagonists & inhibitors)
|